查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1908159

阿兹海默症诊断市场规模、份额和趋势分析报告：按诊断技术、类型、最终用途、地区和细分市场预测（2026-2033 年）

Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report By Diagnostics Technique, By Type, By End User, By Region And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

阿兹海默症诊断市场概览

全球阿兹海默症诊断市场预计到 2025 年价值 92.2 亿美元，预计到 2033 年将达到 215.4 亿美元。

预计从 2026 年到 2033 年，该市场将以 11.23% 的复合年增长率成长。阿兹海默症(AD) 盛行率的上升、生物标记在疾病诊断中的应用日益广泛、个人化产品的普及以及医学影像技术的进步，都是推动阿兹海默症诊断需求成长的部分因素。

政府投资和研发投入的增加正在推动市场进一步成长。阿兹海默症盛行率的上升是市场成长的主要驱动力。随着世界人口老化，对早期精准诊断工具的需求持续成长。根据阿兹海默症协会2024年的报告，失智症的风险老龄化增长而增加，预计美国阿兹海默症患者人数将显着增长。到2050年，65岁及以上人口预计将达到8,200万，高于2022年的5,800万。到2030年，所有婴儿潮世代（1946年至1964年出生）都将年满65岁，这使得该年龄层成为老年痴呆症失智症风险最高的族群。

近年来，针对阿兹海默症根本病因的新疗法研发取得了显着进展。 2023年1月，美国食品药物管理局（FDA）加速核准了由卫材Eisai , Ltd.）和渤健公司（Biogen）联合研发的药物lecanemab上市。Eisai已在日本申请生产和销售核准，并获得了厚生劳动省（MHLW）的优先审查资格。然而，这些药物的有效应用和广泛推广需要能够检测大脑中β-淀粉样蛋白（Aβ）累积的技术。传统的检测方法，例如脑脊髓液（CSF）检测和淀粉样蛋白PET扫描，费用昂贵且具有侵入性，因此人们越来越需要更简单、更非侵入性的诊断方法。

阿兹海默症在全球范围内日益加重，因此早期发现和准确诊断显得尤为重要。基因组学、蛋白质组学和代谢体学的进步正在拓展生物标记在疾病诊断中的应用。特别是，利用正子断层扫描（PET）影像技术检测脑脊髓液中的β-淀粉样蛋白和Tau蛋白等生物标记物，在阿兹海默症诊断中发挥关键作用。此外，各公司正在推出创新的生物标记检测方法，以支援正在进行的临床试验。 2024年3月，LabCorp推出了pTau217血液生物标记检测，旨在加快阿兹海默症的诊断速度，并提高临床检测效率。该检测有望提高阿兹海默症检测的准确性和速度，从而实现及时治疗和疾病管理。

个人化医疗的兴起凸显了生物标记在患者分类、治疗选择和治疗后续观察中的重要性。这一趋势预计将推动生物标誌物市场的扩张。 2023年发表在《阿兹海默症杂誌》上的一项研究强调了精准医疗的作用，精准医疗会考虑遗传、环境和生活方式因素对疾病进展的影响。同样，2021年10月的一项研究提案，Bumetanide（一种FDA核准的口服利尿剂）可能是一种治疗方法阿兹海默症药物。一项由美国国家老龄研究所（NIA）资助的研究分析了脑组织样本和FDA认证核可药，以探索现有药物再利用的潜力，凸显了精准医疗在治疗阿兹海默症的潜力。

影像分析和机器学习演算法的进步正在透过神经影像成像技术提高阿兹海默症诊断的准确性和可靠性。诊断方法正从传统的认知评估发展到先进的神经影像和脑脊髓液（CSF）检测，从而能够更早发现疾病。 2023年6月，罗氏公司获得美国食品药物管理局（FDA）核准，其研发的脑脊髓液检测可测量55岁及以上人群中β-淀粉样蛋白和Tau蛋白的水平，这两种蛋白是阿兹海默症病理的关键生物标记。此检测有助于及时诊断和製定治疗方案。这些技术进步对于改善阿兹海默症的检测和管理至关重要。

持续的研究和技术创新正在推动阿兹海默症诊断和治疗市场的扩张。各公司不断推出新的检测方法和产品，同时也积极进行策略合作、併购和投资。 2024年2月，《MedPage Today》的一篇报导重点介绍了血液生物标记在阿兹海默症研究和临床应用中的诊断潜力。主要企业正致力于推动血液生物标记技术的进步，以提升全球诊断能力。 2023年8月，C2N Diagnostics公司发布了PrecivityAD2血液检测，其准确性可与PET扫描和脑脊髓液检测相媲美。该检测旨在评估认知能力下降和阿兹海默症症状的患者，从而推动该领域诊断技术的进一步发展。

目录

第一章调查方法和范围

第二章执行摘要

第三章阿兹海默症诊断市场的变数、趋势和范围

  • 市场谱系展望
    • 母市场展望
    • 相关及附随市场展望
  • 市场动态
  • 阿兹海默症诊断市场分析工具
    • 产业分析：波特五力模型
    • PESTEL 分析
  • 阿兹海默症诊断市场：应用案例分析

第四章阿兹海默症诊断市场：诊断技术估算与趋势分析

  • 按诊断技术分類的市场份额（2025 年和 2033 年）
  • 全球阿兹海默症诊断市场：按诊断技术分類的展望
  • 市场规模、预测与趋势分析（2021-2033）
  • 生物标誌物
    • 脑脊髓液生物标记
    • 血液生物标记
  • 成像技术
  • 基因检测
  • 认知功能评估测试

第五章阿兹海默症诊断市场：按类型分類的估计和趋势分析

  • 按类型分類的市场份额（2025 年和 2033 年）
  • 全球阿兹海默症诊断市场：按类型分類的展望
  • 市场规模、预测与趋势分析（2021-2033）
  • 分诊
  • 诊断
  • 筛检

第六章：阿兹海默症诊断市场：依最终用途分類的估计与趋势分析

  • 按最终用途分類的市场份额（2025 年和 2033 年）
  • 全球阿兹海默症诊断市场：终端用户展望
  • 市场规模、预测与趋势分析（2021-2033）
  • 医院
  • 诊断实验室
  • 学术和研究机构

第七章阿兹海默症诊断市场：区域、估计和趋势分析

  • 区域市场占有率分析（2025 年和 2033 年）
  • 区域市场概览
  • 全球市场概览（按地区划分）
  • 市场规模及预测趋势分析，2021-2033年
  • 北美洲
    • 北美：SWOT 分析
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲：SWOT分析
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 亚太地区：SWOT分析
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 中东和非洲：SWOT 分析
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争情势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商概况
    • 主要经销商和通路合作伙伴名单
    • 主要公司市占率分析，2025 年
    • Quest Diagnostics Incorporated
    • Laboratory Corporation of America Holdings
    • F. Hoffmann-La Roche Ltd.
    • Siemens Healthineers AG
    • C2N diagnostics
    • FujireBio
    • Bristol Myers Squibb Company
    • Quanterix
    • Sysmex
    • Lantheus
Product Code: GVR-4-68040-323-7

Alzheimer's Disease Diagnostics Market Summary

The global Alzheimer's disease diagnostics market size was estimated at USD 9.22 billion in 2025 and is expected to reach USD 21.54 billion by 2033, projected to grow at a CAGR of 11.23% from 2026 to 2033. Increasing prevalence of Alzheimer's Disease (AD), growing use of biomarkers in disease diagnostics, growing adoption of personalized products, and increasing technological advancements in medical imaging are some of the factors expected to drive the demand for Alzheimer's diagnostics.

Increasing government investments and R&D studies is further propelling growth. The rising prevalence of Alzheimer's disease is a key driver of market growth. As the global population ages, the demand for early and accurate diagnostic tools continues to increase. According to the 2024 Alzheimer's Association, dementia risk rises with age, and the number of Americans with Alzheimer's is expected to grow significantly. By 2050, the population aged 65 and older is projected to reach 82 million, up from 58 million in 2022. By 2030, all baby boomers (born between 1946 and 1964) will be 65 or older, the age group most susceptible to Alzheimer's dementia.

In recent years, there has been significant progress in developing novel therapeutic drugs targeting the root causes of Alzheimer's disease. In January 2023, the U.S. FDA granted accelerated approval to lecanemab, a treatment co-developed by Eisai Co., Ltd. and Biogen Inc. Eisai also applied for manufacturing and marketing approval in Japan, where the drug received priority review from the Ministry of Health, Labour and Welfare (MHLW). However, effective use and distribution of these drugs require technology to detect amyloid-beta (AB) accumulation in the brain. Conventional testing methods, such as cerebrospinal fluid (CSF) testing and amyloid PET scans, are costly and invasive, increasing the demand for simpler, less invasive diagnostic approaches.

The growing global burden of Alzheimer's has intensified the need for early detection and precise diagnosis. Advances in genomics, proteomics, and metabolomics have expanded the use of biomarkers in disease diagnostics. Biomarkers, particularly those detecting amyloid-beta and tau proteins in CSF through positron emission tomography (PET) imaging, play a crucial role in Alzheimer's diagnosis. In addition, companies are launching innovative biomarker tests to support ongoing clinical trials. In March 2024, Labcorp introduced the pTau217 blood biomarker test, designed to accelerate Alzheimer's diagnosis and improve clinical trial efficiency. This test is expected to enhance the accuracy and speed of detecting Alzheimer's, ensuring timely treatment and disease management.

The rise of personalized medicine has underscored the importance of biomarkers in patient categorization, treatment selection, and therapeutic monitoring. This trend is expected to drive the biomarkers market's expansion. A 2023 study published in the Journal of Alzheimer's Disease emphasized the role of precision medicine in Alzheimer's, considering genetic, environmental, and lifestyle factors in disease progression. Similarly, an October 2021 study suggested bumetanide, an FDA-approved oral diuretic, as a potential treatment for Alzheimer's. Research funded by the National Institute on Aging (NIA) analyzed brain tissue samples and FDA-approved drugs to explore repurposing opportunities, highlighting precision medicine's potential in Alzheimer's treatment.

Advancements in image analysis and machine learning algorithms have enhanced the accuracy and reliability of Alzheimer's diagnostics through neuroimaging techniques. Diagnostic approaches have evolved from traditional cognitive assessments to advanced neuroimaging and CSF assays, allowing for early disease identification. In June 2023, Roche received FDA clearance for its CSF assay, which aids in timely diagnosis and treatment decision-making by measuring beta-amyloid and tau protein levels, two key biomarkers of Alzheimer's pathology, in individuals aged 55 and older. These technological advancements are crucial for improving Alzheimer's detection and management.

Ongoing research and technological innovations are driving the expansion of the Alzheimer's diagnostics and therapeutics market. Companies continue to introduce new tests and products while engaging in strategic collaborations, mergers, and investments. A February 2024 MedPage Today article highlighted the diagnostic potential of blood biomarkers in Alzheimer's research and clinical applications. Key industry players are advancing blood biomarker technologies to enhance global diagnostic capabilities. In August 2023, C2N Diagnostics launched the PrecivityAD2 blood test, designed to match the accuracy of PET scans and CSF tests. This test aims to assess patients with cognitive decline and Alzheimer's symptoms, further strengthening diagnostic advancements in the field.

Global Alzheimer's Disease Diagnostics Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global Alzheimer's disease diagnostics market report on the basis of diagnostics technique, type, end use, and region.

  • Diagnostics Technique Outlook (Revenue, USD Million, 2021 - 2033)
  • Biomarkers
    • CSF Biomarkers
    • Blood-Based Biomarkers
  • Imaging Techniques
  • Genetic Testing
  • Cognitive Assessment Tests
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Triage
  • Diagnosis
  • Screening
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Regional Outlook (Revenue in USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Diagnostics Technique
    • 1.2.2. Type
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Diagnostics Technique outlook
    • 2.2.2. Type outlook
    • 2.2.3. End Use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Alzheimer's Disease Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of Alzheimer disease
      • 3.2.1.2. Increasing use of biomarkers in diagnosis
      • 3.2.1.3. Growing adoption of personalized products
      • 3.2.1.4. Growing R&D studies and government investments
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Stringent regulations
  • 3.3. Alzheimer's Disease Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
  • 3.4. Alzheimer's Disease Diagnostics Market: Case Study Analysis

Chapter 4. Alzheimer's Disease Diagnostics Market: Diagnostics Technique Estimates & Trend Analysis

  • 4.1. Diagnostics Techniques Market Share, 2025 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Alzheimer's Disease Diagnostics Market: Diagnostics Technique Movement Analysis
  • 4.4. Alzheimer's Disease Diagnostics Market Size & Trend Analysis, by diagnostic technique, 2021 to 2033 (USD Million)
  • 4.5. Biomarker
    • 4.5.1. Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. CSF Biomarkers
      • 4.5.2.1. CSF Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Blood Based Biomarker
      • 4.5.3.1. Blood Based Biomarker Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Imaging Techniques
    • 4.6.1. Imaging Techniques Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Genetic Testing
    • 4.7.1. Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Cognitive Assessment Tests
    • 4.8.1. Cognitive Assessment Tests Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Alzheimer's Disease Diagnostics Market: Type Estimates & Trend Analysis

  • 5.1. Type Market Share, 2025 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Alzheimer's Disease Diagnostics Market by Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Triage
    • 5.5.1. Triage Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Diagnosis
    • 5.6.1. Diagnosis Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Screening
    • 5.7.1. Screening Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Alzheimer's Disease Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2025 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Alzheimer's Disease Diagnostics Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Hospitals
    • 6.5.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Diagnostic Laboratories
    • 6.6.1. Diagnostic Laboratories Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Academic and Research Institutes
    • 6.7.1. Academic and Research Institutes Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Alzheimer's Disease Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033
  • 7.5. North America
    • 7.5.1. North America: SWOT Analysis
    • 7.5.2. U.S.
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/Reimbursement
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. Canada
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/Reimbursement
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.4. Mexico
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/Reimbursement
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Europe
    • 7.6.1. Europe: SWOT Analysis
    • 7.6.2. UK
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/Reimbursement
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.3. Germany
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/Reimbursement
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.4. France
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/Reimbursement
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.5. Italy
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/Reimbursement
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.6. Spain
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/Reimbursement
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.7. Norway
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/Reimbursement
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.8. Sweden
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/Reimbursement
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.9. Denmark
      • 7.6.9.1. Key country dynamics
      • 7.6.9.2. Regulatory framework/Reimbursement
      • 7.6.9.3. Competitive scenario
      • 7.6.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Asia Pacific: SWOT Analysis
    • 7.7.2. Japan
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/Reimbursement
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. China
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/Reimbursement
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. India
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/Reimbursement
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.5. Australia
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/Reimbursement
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.6. South Korea
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/Reimbursement
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.7. Thailand
      • 7.7.7.1. Key country dynamics
      • 7.7.7.2. Regulatory framework/Reimbursement
      • 7.7.7.3. Competitive scenario
      • 7.7.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Latin America: SWOT Analysis
    • 7.8.2. Brazil
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/Reimbursement
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/Reimbursement
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9. MEA
    • 7.9.1. MEA: SWOT Analysis
    • 7.9.2. South Africa
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/Reimbursement
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.3. Saudi Arabia
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/Reimbursement
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.4. UAE
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/Reimbursement
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.5. Kuwait
      • 7.9.5.1. Key country dynamics
      • 7.9.5.2. Regulatory framework
      • 7.9.5.3. Competitive scenario
      • 7.9.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2025
    • 8.3.4. Quest Diagnostics Incorporated
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Services benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Laboratory Corporation of America Holdings
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Services benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. F. Hoffmann-La Roche Ltd.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Services benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Siemens Healthineers AG
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Services benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. C2N diagnostics
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Services benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. FujireBio
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Services benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Bristol Myers Squibb Company
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Services benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Quanterix
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Services benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Sysmex
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Services benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Lantheus
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Services benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Alzheimer's disease diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 4 North America Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 5 North America Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 6 U.S. Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 7 U.S. Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 8 U.S. Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 9 Canada Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 10 Canada Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 11 Canada Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 12 Mexico Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 13 Mexico Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 14 Mexico Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Europe Alzheimer's disease diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 16 Europe Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 17 Europe Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 18 Europe Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Germany Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 20 Germany Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 21 Germany Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 22 UK Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 23 UK Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 24 UK Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 25 France Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 26 France Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 27 France Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 28 Italy Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 29 Italy Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 30 Italy Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 31 Spain Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 32 Spain Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 33 Spain Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 34 Denmark Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 35 Denmark Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 36 Denmark Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 37 Sweden Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 38 Sweden Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 39 Sweden Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 40 Norway Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 41 Norway Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 42 Norway Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific Alzheimer's disease diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 47 China Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 48 China Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 49 China Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 50 Japan Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 51 Japan Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 52 Japan Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 53 India Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 54 India Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 55 India Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 56 South Korea Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 57 South Korea Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 58 South Korea Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 59 Australia Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 60 Australia Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 61 Australia Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 62 Thailand Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 63 Thailand Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 64 Thailand Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 65 Latin America Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 66 Latin America Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 67 Latin America Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 68 Brazil Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 69 Brazil Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 70 Brazil Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 71 Argentina Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 72 Argentina Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 73 Argentina Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 74 MEA Alzheimer's disease diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 75 MEA Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 76 MEA Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 77 MEA Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 78 South Africa Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 79 South Africa Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 80 South Africa Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 81 Saudi Arabia Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 82 Saudi Arabia Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 84 UAE Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 85 UAE Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)
  • Table 86 UAE Alzheimer's disease diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 87 Kuwait Alzheimer's disease diagnostics market, by diagnostics technique, 2021 - 2033 (USD Million)
  • Table 88 Kuwait Alzheimer's disease diagnostics market, by type, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Alzheimer's disease diagnostics market: market outlook
  • Fig. 14 Alzheimer disease diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Alzheimer's disease diagnostics market driver impact
  • Fig. 20 Alzheimer's disease diagnostics market restraint impact
  • Fig. 21 Alzheimer's disease diagnostics market strategic initiatives analysis
  • Fig. 22 Alzheimer's disease diagnostics market: Diagnostics technique movement analysis
  • Fig. 23 Alzheimer's disease diagnostics market: Diagnostics technique outlook and key takeaways
  • Fig. 24 Biomarkers market estimates and forecast, 2021 - 2033
  • Fig. 25 CSF biomarkers estimates and forecast, 2021 - 2033
  • Fig. 26 Blood based biomarkers market estimates and forecast, 2021 - 2033
  • Fig. 27 Imaging techniques estimates and forecast, 2021 - 2033
  • Fig. 28 Genetic testing market estimates and forecast, 2021 - 2033
  • Fig. 29 Cognitive assessment tests market estimates and forecasts, 2021 - 2033
  • Fig. 30 Alzheimer's disease diagnostics market: Test type movement analysis
  • Fig. 31 Alzheimer's disease diagnostics market: Test type outlook and key takeaways
  • Fig. 32 Triage market estimates and forecasts, 2021 - 2033
  • Fig. 33 Diagnosis market estimates and forecasts, 2021 - 2033
  • Fig. 34 Screening market estimates and forecasts, 2021 - 2033
  • Fig. 35 Alzheimer's disease diagnostics market: End use movement analysis
  • Fig. 36 Alzheimer's disease diagnostics market: End- use outlook and key takeaways
  • Fig. 37 Hospitals market estimates and forecasts, 2021 - 2033
  • Fig. 38 Diagnostic laboratories market estimates and forecasts, 2021 - 2033
  • Fig. 39 Academic and research institutes market estimates and forecasts, 2021 - 2033
  • Fig. 40 Global Alzheimer's disease diagnostics market: Regional movement analysis
  • Fig. 41 Global Alzheimer's disease diagnostics market: Regional outlook and key takeaways
  • Fig. 42 Global Alzheimer's disease diagnostics market share and leading players
  • Fig. 43 North America, by country
  • Fig. 44 North America Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 45 U.S. key country dynamics
  • Fig. 46 U.S. Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 47 Canada key country dynamics
  • Fig. 48 Canada Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 49 Mexico key country dynamics
  • Fig. 50 Mexico Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 51 Europe Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 52 UK key country dynamics
  • Fig. 53 UK Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 54 Germany key country dynamics
  • Fig. 55 Germany Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 56 France key country dynamics
  • Fig. 57 France Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 58 Italy key country dynamics
  • Fig. 59 Italy Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 60 Spain key country dynamics
  • Fig. 61 Spain Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 62 Denmark key country dynamics
  • Fig. 63 Denmark Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 64 Sweden key country dynamics
  • Fig. 65 Sweden Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 66 Norway key country dynamics
  • Fig. 67 Norway Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 68 Asia Pacific Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 69 China key country dynamics
  • Fig. 70 China Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 71 Japan key country dynamics
  • Fig. 72 Japan Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 73 India key country dynamics
  • Fig. 74 India Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 75 Thailand key country dynamics
  • Fig. 76 Thailand Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 77 South Korea key country dynamics
  • Fig. 78 South Korea Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 79 Australia key country dynamics
  • Fig. 80 Australia Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 81 Latin America Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 82 Brazil key country dynamics
  • Fig. 83 Brazil Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 84 Argentina key country dynamics
  • Fig. 85 Argentina Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 86 Middle East and Africa Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 87 South Africa key country dynamics
  • Fig. 88 South Africa Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 89 Saudi Arabia key country dynamics
  • Fig. 90 Saudi Arabia Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 91 UAE key country dynamics
  • Fig. 92 UAE Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 93 Kuwait key country dynamics
  • Fig. 94 Kuwait Alzheimer's disease diagnostics market estimates and forecasts, 2021 - 2033
  • Fig. 95 Market share of key market players- Alzheimer's disease diagnostics market